Arsenal Capital Partners’ £178.8 Million Takeover Of Cello Health plc


Ashurst advised Rothschild & Co in relation to the recommended takeover of Cello Health plc by Arsenal Capital Partners.

The cash offer, which was announced today, values the current issued share capital of Cello Health plc at approximately £178.8.

Cello Health plc is a global healthcare-focused advisory group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. It serves 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, devices and other key non-healthcare clients. Cello enables clients to differentiate their assets and drive brand success, operating through nearly 1,000 highly skilled professionals utilising the latest thinking, technology and digital solutions. Its services are delivered from an office network in the UK, USA, and Asia.

The Ashurst team was led by corporate partner Tom Mercer (Picture), assisted by senior associate Aimee Carroll-Hewitt and associate Millie Gibbs.

Involved fees earner: Aimee Carroll-Hewitt – Ashurst; Millie Gibbs – Ashurst; Tom Mercer – Ashurst;

Law Firms: Ashurst;

Clients: Arsenal Capital Partners;